Short answer
Protagonist Therapeutics, Inc (PTGX) filed its Q2 2026 10-Q quarterly report on Aug 5, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $213M (up 3749.2% year over year) with net income of $163M.
Q2 2026 key financials · XBRL
- Revenue
- $213M
- +3749.2% YoY · +278.7% QoQ
- Net income
- $163M
- +568.3% YoY · +4204.8% QoQ
- Operating margin
- 74.4%
- EPS (diluted)
- $2.30
- +525.9% YoY · +4500.0% QoQ
Source: XBRL data from the Protagonist Therapeutics, Inc (PTGX) Q2 2026 10-Q on SEC EDGAR. USD.
Protagonist Therapeutics, Inc Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- Takeda commercialization dependence added after April 2026 opt-out, shifting rusfertide economics to 14%–29% royalties and $775 million milestones
- Rusfertide commercialization risk: Takeda controls development, supply, resource allocation, and potential agreement termination
- Pharmaceutical tariff exposure: tariffs up to 100% authorized on covered imports effective July 31, 2026
- Clinical and manufacturing disruption risk from tariffs, inflation, geopolitical conflicts, and supply-chain interruptions
- Financing risk: deteriorating equity and credit markets could make funding more costly and dilutive or delay clinical plans
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Protagonist Therapeutics, Inc quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.